Background: Concurrent chemoradiotherapy (CCRT) for locoregionally advanced esophageal or gastroesophageal junction cancer produces high locoregional control rates but suboptimal distant metastatic control (DMC) and overall survival. This phase II study added gefitinib (G) to our previously tested CCRT regimen in an effort to improve these outcomes. Methods: Eligibility required T3, N1, or M1a esophageal or gastroesophageal junction squamous cell or adenocarcinoma staged by esophageal ultrasound and positron emission tomography/computed tomography. Four-day continuous intravenous infusions of cisplatin (20 mg/m 2 /d) and fluorouracil (1000 mg/m 2 /d) began on day 1 of preoperative radiation (30 Gy and 1.5 Gy bid). Surgery followed in 4 to 6 weeks, and an identical course of CCRT 6 to 10 weeks postoperatively. G 250 mg/d was given with preoperative CCRT for 4 weeks and restarted with postoperative therapy for 2 years. Results were retrospectively compared with our historical series of 93 patients given CCRT without G. Results: Between April 2003 and July 2006, 80 patients were enrolled. Patient and tumor characteristics were similar to our historical series. G did not increase toxicity except for development of rash in 42 (53%) and diarrhea in 44 (55%) 3-year Kaplan-Meier estimates (G versus non-G treated patients) included: overall survival (42% versus 28%, p ϭ 0.06), DMC (40% versus 32%, p ϭ 0.33), and locoregional control (76% versus 77%, p ϭ 0.74). Intolerance for G maintenance occurred in 48% of patients. Patients who experienced G related diarrhea appeared to have improved outcomes.
lethal malignancy rapidly increasing in incidence. As in most solid tumors, survival is predicted by disease stage at presentation. In early stage disease, surgical resection alone is often curative. For patients with locoregionally advanced disease, however, fewer than 20% are cured with surgical resection alone, and the optimal treatment approach is not well defined. 1, 2 Over the last 20 years, clinical trials have suggested that the addition of perioperative chemotherapy or chemoradiation to surgery may improve survival. [3] [4] [5] [6] [7] [8] Since 1999 at the Cleveland Clinic, patients with locoregionally advanced esophagus or GEJ cancer have been treated with perioperative multiagent chemotherapy and split course radiation. Using this regimen, we achieved a 3-year locoregional control (LRC) rate of 86% but an overall survival (OS) of only 28%, with most patients developing distant metastasis. 9 This pattern of treatment failure suggests the need for better systemic therapy.
The epidermal growth factor receptor (EGFR) is overexpressed in 60 to 70% of esophageal squamous cell carcinomas, 10, 11 and 30 to 70% of distal esophageal or GEJ adenocarcinomas. 12, 13 This suggests a role for the clinically available monoclonal antibody EGFR inhibitors cetuximab and panitumimab or the oral tyrosine kinase EGFR inhibitors gefitinib (G) and erlotinib. Limited phase II data in patients with metastatic esophageal cancer have suggested drug activity, with reported objective response rates of approximately 10% and disease control rates of 30%, 13, 14 similar to our Cleveland Clinic experience. 15 These agents' relatively favorable toxicity profile and demonstrated activity in metastatic disease suggested to us that their addition to our definitive perioperative concurrent chemoradiotherapy regimen might favorably impact the high rate of distant metastatic failure and led to the development of this trial. The goal of this trial was to examine OS and distant metastatic control (DMC) among patients with locally advanced esophageal or gastroesophageal cancer treated with perioperative concurrent chemotherapy radiation and G followed by maintenance G.
PATIENTS AND METHODS

Study Design
This is an open label phase II study of patients with locoregionally advanced esophageal or GEJ carcinoma. Support for this research and the experimental drug (G) was provided by AstraZeneca Pharmaceuticals (Reference number: IRUSIRES0250). The primary objective was to determine OS and DMC among patients enrolled. Secondary objectives included toxicity, pathologic response rates, and long-term G tolerance. The results were retrospectively compared with a historical cohort of 93 patients, with identical eligibility criteria, who were treated on our previous phase II protocol with the same concurrent chemoradiotherapy and surgery regimen without G. 9
Patients
Patients with previously untreated, histologically confirmed squamous cell or adenocarcinoma of the esophagus or GEJ were eligible for participation. Enrollment required normal renal, bone marrow, and hepatic function; adequate cardiac and pulmonary reserve to undergo surgical resection; and an Eastern Cooperative Oncology Group performance status of 0 or 1.
A thoracic surgeon, radiation oncologist, and medical oncologist evaluated each patient before enrollment. A medical history, physical examination, complete blood count, serum chemistries with hepatic function panel, chest radiograph, and pulmonary function testing were obtained. Disease staging included an esophagogastroduodenoscopy with endoscopic ultrasound, computed tomography (CT) of the chest, abdomen and pelvis, and whole body positron emission tomographic (PET) scanning. Bronchoscopy was performed in patients whose symptoms, tumor extent, or location suggested a risk of airway involvement. The American Joint Committee on Cancer 2002 staging system was used to assign a clinical disease stage. 16 Participation required T3, N1, or M1a disease. Patients with hematogenous metastases (M1b) were ineligible.
This protocol was approved and reviewed yearly by the Cleveland Clinic Institutional Review board. All patients signed written informed consent. Figure 1 illustrates the treatment schema. Concurrent chemoradiation was administered in a split course fashion before and after surgery. Preoperative radiotherapy was delivered in 1.5 cGy fractions, twice daily over 12 days to a dose of 30 Gy. A 96-hour continuous intravenous infusion of cisplatin (20 mg/m 2 /d) and fluorouracil (1000 mg/m 2 /d) was begun on the first day of radiation. The delivery of two drugs, both by means of continuous intravenous infusion required and was facilitated by hospitalization on a dedicated inpatient chemotherapy administration service at our institution. G 250 mg daily orally was started on the first day of concurrent chemoradiation and continued for 4 weeks.
Treatment
Radiation therapy was administered using Ն6 megavoltage photon beams generated by a linear accelerator. Preoperative radiation fields encompassed the primary tumor, involved nodal areas, and regional lymphatic areas at risk for microscopic disease involvement. A 5 cm cephalocaudal and 2 to 2.5 cm radial margin were applied in treating the primary tumor. The at-risk nodal areas treated in patients with proximal esophageal cancers were the supraclavicular, lower cervical, and upper mediastinal areas. For mid esophageal tumors, all mediastinal lymph node stations were irradiated. All lower mediastinal nodal stations and celiac lymph nodes were irradiated in patients with distal or GEJ primary tumors. For two-dimensional planning, dosimetry was generated at the central axis of the field, the center of the target volume, and at planes 1.0 and 1.5 cm inside the superior and inferior margins of the treatment fields. For three-dimensional plans, gross tumor volume with lymph nodes at risk was enclosed in a planning tumor volume covered by Ͼ95% isodose line. Tissue inhomogeneity corrections were not used. Postoperative treatment volumes were planned for each patient and replicated preoperative field coverage of areas at risk.
Patients were evaluated weekly during radiation therapy to both monitor and treat any toxicities that developed. Any febrile episode during neutropenia necessitated hospitalization for intravenous antibiotics. Patients with poor oral intake from mucositis or dysphagia resulting in dehydration were also hospitalized. Four to six weeks after completion of the first course of radiation therapy, patients were restaged to confirm the absence of distant metastases and if appropriate were taken to surgery.
In general, a near-complete esophagectomy was planned and accomplished through simultaneous left thoracoabdominal and left neck incisions. In patients with upper or midthoracic tumors, at risk for involvement of the airway or the aortic arch, a right thoractomy followed by a midline laparotomy and left neck incision for reconstruction was preferred. Surgical margins were examined intraoperatively with the goal of achieving disease-free proximal, distal, and soft tissue margins of resection. Lymphadenectomy was performed in a continuous fashion and extended from the aortic arch to the celiac axis when a left-sided thoractomy and left neck incision were made. Alternatively, lymph node dissection was extended to the apex of the right chest in the setting of a right-sided thoracotomy. The stomach was used for reconstruction, and the anastomosis was performed, when possible, at the thoracic inlet to place it outside the radiation fields. For GEJ cancers with extensive gastric involvement requiring gastrectomy, the esophagojejunal anastomosis was constructed in the left chest above the inferior pulmonary vein but within the radiation fields.
The postoperative stage was determined after pathologic examination of the resected specimen. A pathologic response to induction chemoradiation required improvement in T, N, or M1a designation without a reciprocal increase in any other descriptor.
Postoperative chemoradiation was begun 6 to 10 weeks after surgical resection using a regimen identical to the preoperative treatment. Postoperative radiation was delivered to the tumor bed. In patients with positive margins, the anastomosis was included in the treatment field. Patients completing preoperative therapy, who could not undergo surgery either for medical reasons or because of locoregionally unresectable disease identified at surgery, also received postoperative therapy in this fashion. G 250 mg daily was restarted on the first day of postoperative chemoradiation and continued for a planned 2-year course of maintenance therapy. Most patients develop distant disease recurrence in the first 2 years after completion of multimodality treatment, thus the 24-month duration of maintenance therapy, similar to trials using maintenance G after definitive chemoradiation for locally advanced head and neck squamous cell carcinoma. 17, 18 After completion of radiation therapy, patients were followed up every 3 months for evidence of disease recurrence and to monitor any treatment-related toxicities. Radiographic imaging and endoscopic examinations were performed if clinically indicated. Any disease recurrence was characterized as locoregional, distant, or both.
Statistical Considerations
In our phase II study that examined this perioperative chemoradiotherapy regimen without G, we observed a median OS of 15 months and a median DMC of 13 months. A sample size of 80 patients was needed to have 78% power to detect an increase in the median OS to 24 months and 85% power to detect an increase to 25 months. This sample size also had 78% and 85% power to identify an increase in DMC to 20 and 21 months, respectively. It is important to point out that this was not a prospective randomized trial comparing perioperative concurrent chemoradiation with and without G. However, for the purpose of hypothesis generation retrospective comparisons have been made with our historical series of patients treated on a previously published phase II trial with identical eligibility criteria, using the same perioperative concurrent chemoradiation regimen without G.
Categorical variables are summarized as frequency counts and percentages and compared between studies using the 2 test. Continuous variables are summarized as the median and range and compared using the t test or Wilcoxon rank sum test. Four outcomes were assessed: freedom from recurrence (FFR), LRC, DMC, and OS. The events defining these outcomes were any recurrence for FFR, locoregional recurrence for LRC, distant recurrence for DMC, and allcause mortality for OS. All outcomes were calculated relative to the start of the first course of chemoradiotherapy. Outcomes were estimated using the Kaplan-Meier method and compared between studies using the log-rank test.
Additional analyses were performed among patients in this study. G intolerance was assessed and defined by the event of G discontinuation for reasons unrelated to disease progression or recurrence. Exploratory Kaplan-Meier analyses were also performed examining the study outcomes for pathologic stage, pathologic response, and G-related rash or diarrhea.
Analyses were done using SAS software (SAS Institute, Inc., Cary, NC). A p value of Ͻ0.05 was used to indicate statistical significance, and unless otherwise noted all statistical tests were two sided.
RESULTS
Between April 2003 and July 2006, 80 patients were enrolled. Table 1 details patient and tumor characteristics, which were, in general, very similar to our previously reported cohort Table 2 . Seventythree patients (91%) underwent surgical resection on the current trial. Seven patients did not undergo surgery; four due to the development of metastatic disease before surgery, one due to hepatic cirrhosis identified during abdominal exploration, one due to a pneumonia compromising pulmonary function, and one due to protracted recovery after preoperative therapy. Tumor margins were positive in eight patients (11%). Postoperative complications developed in 33 patients (45%) including a wound infection in six patients, chyle leak in five, pneumonia in three, and pleural effusion in three. Although we reported four postoperative deaths (5%) in our historical series without G, there were no postoperative deaths in the current series.
Pathologic response rates did not differ between these two clinical trials. Complete pathologic clearance of all disease was found at the time of surgery in 8% of the patients from the current series and in 7% of the patients from the historical cohort.
Among the 73 G patients who underwent surgical resection, 60 (82%) completed the postoperative chemoradiation course. Two patients (3%) began the course but could not complete it due to chest pain during chemotherapy attributed to 5-fluorouracil cardiac toxicity. The remaining 11 (15%) patients were unable to receive postoperative therapy; six due to protracted postoperative recovery and two due to development of metastatic disease. One patient declined postoperative treatment, another developed radiation pneumonitis that precluded postoperative therapy and G, and one patient had already been taken off study for possible 5-fluorouracil cardiac toxicity during preoperative treatment.
The median OS and DMC for this G-treated cohort were 24.2 and 20.1 months, respectively. With a median follow-up among living patients in the G-treated group of 43 months (range 23-64 months) and 77 months (range 55-95 months) for the historical cohort not treated with G, the 3-year Kaplan-Meier outcome estimates for the G and non-G groups are OS 42% versus 28% (p ϭ 0.06) and DMC 40% versus 32% (p ϭ 0.33), respectively (Figures 2A, B) . LRC was 76% versus 77% (p ϭ 0.74) and FFR 38% versus 30% (p ϭ 0.23). 
Toxicity
Perioperative chemoradiotherapy-related toxicity for both the G and non-G treated patients is presented in Table 3 . In general, G-treated patients experienced less mucositis, myelosuppresion, neutropenic fever, and unplanned hospitalization, although rash developed in 42 (52%) and diarrhea in 44 (55%) patients given G. Most G-related toxicity was mild (grade 1). Only one patient experienced grade 3 diarrhea, four had grade 2 diarrhea, and one experienced grade 2 skin rash.
Maintenance G was discontinued per protocol for reasons such as delayed postoperative recovery precluding postoperative chemoradiotherapy or disease progression. Premature discontinuation of maintenance G for other reasons such as patient refusal or intolerable toxicity was more common and was considered to be G intolerance. The G intolerance rate was 48%. G compliance was assessed by pill counts, which demonstrated that patients taking G took a median 97% (range 46 -100%) of their prescribed pills.
On univariate analysis, significant differences in the endpoints of interest favored patients with less advanced pathologic stage disease. The 3-year estimate for OS was 66% for patients with T0-3N0M0 disease, 36% for T0-3N1M0, and 17% for T4or M1a (p ϭ 0.002). Similarly, 3-year DMC (76% versus 30% versus 8%, p Ͻ0.0001), LRC (90% versus 79% versus 34%, p ϭ 0.015), and FFR (71%versus 30% versus 8% p Յ0.001) were superior among patients staged T0-3N0M0 at resection compared with T0-3N1M0 and T4 orM1a. If patients with a partial or complete response to preoperative treatment are compared with those with no response or progressive disease, an improvement in the 3-year DMC (34% versus 54%, p ϭ 0.034) and a trend toward improved FFR (34% versus 49% p ϭ 0.05) and OS (39% versus 51% p ϭ 0.15) were observed.
No differences in outcome were noted in patients who developed G cutaneous toxicity. However, patients who developed diarrhea seemed to have improved OS and DMC (Figures 3A, B) . Although diarrhea was the most common toxicity prompting premature discontinuation of G, there was no statistical difference in G tolerance or compliance among patients who experienced diarrhea and those who did not.
DISCUSSION
The predominant pattern of failure after multimodality treatment of locoregionally advanced esophageal cancer has been distant metastasis, both at our institution and elsewhere. This has always suggested to clinical investigators a need for more effective systemic therapy. Generally, the approach has been to increase the exposure to systemic chemotherapy, often by adding induction chemotherapy to the preoperative chemoradiotherapy. 19 Although theoretically sound, this approach prolongs the duration of therapy and adds not insignificant toxicity to the overall treatment. We chose a different approach, opting to address DMC through the use of an easily administered oral EGFR inhibitor with a favorable toxicity profile. Acknowledging the limitations of a retrospective, nonrandomized comparison, it is of interest that a survival benefit for the G cohort was suggested, despite similar rates of distant metastasis. The challenge of appropriately selecting patients for EGFR targeted therapies may contribute to our findings. Large phase III clinical studies of unselected patients treated for refractory metastatic non-small cell lung cancer using the oral EGFR inhibitors G and erlotinib have consistently demonstrated response rates in the 10 to 15% range. 20 -22 Asian ethnicity, female sex, adenocarcinoma histology, lack of tobacco exposure, and sensitizing somatic mutations of the EGFR gene have been associated with higher rates of response. The relative homogeneity of the demographic affected by esophageal cancer makes patient selection for EGFR inhibition according to these clinical parameters difficult. EGFR sensitizing mutations are rare and likely unimportant in this disease. The implications of EGFR overexpression, gene amplification, and K-ras status have conflicting correlations with drug responsiveness in other epithelial malignancies and are yet undefined in esophageal cancer. At present, no clinical or molecular markers for EGFR inhibitor responsiveness in this disease have been identified.
One clinical parameter consistently associated with increased response rates is the characteristic cutaneous reaction to EGFR inhibitors. [21] [22] [23] [24] This observation has been made in several epithelial malignancies, independent of the type of EFGR inhibitor used. Although a G rash was not predictive in our trial, improved outcomes were associated with the development of G related diarrhea. Unlike cutaneous toxicity, the gastrointestinal toxicities of EGFR inhibition and their association with response rates and outcome have not been described. Cusatis et al. reported a significantly higher rate of diarrhea and higher serum G levels in patients who possess a polymorphism of the efflux transporter protein ABCG2. It could be postulated that our observed improvement in outcome may relate to increased drug levels and efficacy. 23, 24 Although the EGFR inhibitors have been regarded as drugs with a favorable toxicity profile, long-term maintenance therapy with these agents was not well tolerated in our patient population. Among patients who remained on the drug with no evidence of disease recurrence or progression, only 52% were able to complete the 2-year course of maintenance therapy. Perhaps, the combination of this drug with our aggressive multimodality therapy makes the side effect profile less tolerable as opposed to its use in other settings such as palliative treatment. The inability of patients to complete the course of therapy may also have contributed to the lack of efficacy noted in decreasing the incidence of distant metastasis.
The monoclonal antibody cetuximab has demonstrated synergistic activity with radiation and chemotherapy that has translated into improved clinical outcomes in other epithelial malignancies. [25] [26] [27] However, a similar experience is yet to be described with G, most widely studied in non-small cell lung cancer. G maintenance therapy after definitive chemoradiotherapy in locally advanced non-small cell lung cancer produced inferior outcomes in the prematurely closed Southwest Oncology Group 0023, suggesting that G may result in G1 cell cycle arrest mitigating the efficacy of systemic therapy. 28 It would be difficult to invoke this phenomenon in our patients, because locoregional and distant failure rates were similar to our historical cohort.
The possibility of stage migration must also be addressed in interpreting our retrospective comparison with historical results. Despite the similar tumor characteristics and staging between the G and non-G treated cohorts, integrated PET/CT for disease staging was not used consistently in the historical cohort, having been introduced midway during the patient enrollment period. The improved sensitivity and accuracy of the PET/CT and EUS combination is well established 29 -31 and unrecognized occult metastatic disease at the time of enrollment could have negatively impacted outcomes in the historical series.
A pathologic complete response (pCR) rate of only 8% was achieved in this series, after the single cycle of chemotherapy and only 30 Gy of radiation. It should be pointed out that the pCR rate has been frequently observed to predict for improved survival among patients treated with preoperative chemoradiation, [32] [33] [34] [35] leading to recommendations for intensified efforts to achieve a pCR. This observation, that responders do better than nonresponders, has been frequently made in oncology, with only limited implications, and there is reason for caution when using pCR rates to evaluate the efficacy of an induction treatment regimen. This end point is influenced by the timing and accuracy of pathologic response determination and by the intensity and duration of induction treatment. A pCR is likely to identify patients with more favorable disease biology, destined to do well independent of the type of therapy received, and achievement of a pCR may not so much be the cause of the successful outcome as it is a reflection of that treatment success. Clinical trials that have investigated adjuvant therapy after surgical resection and those that have demonstrated a low pCR rate after preoperative therapy have comparable survival rates as those that report higher pCR rates. 5, 7, 36 Although pCR rates may facilitate reporting of clinical trials, OS is a more accurate reflection of the efficacy of a treatment regimen.
The increased scrutiny of the economic burden of health care delivery appropriately raises the issue of the financial implications of administering this multimodality treatment regimen. Apart from the obvious costs of hospitalization, drug, and drug administration, other incurred expenses not easily quantified include the cost of transportation to receive care, copayments, and income lost from missed days at work. At our institution, the delivery of chemoradiotherapy is facilitated through a dedicated inpatient chemotherapy service. Although no formal cost analysis of this regimen has been performed, it avoids placement of indwelling catheters, decreases transportation costs for twice daily radiation, and allows for inpatient supportive care during chemoradiotherapy, which may avoid unplanned hospitalizations for symptom control. Reducing the cost of cancer care is an integral aspect of improving its availability and outcomes. In addition to focusing efforts toward appropriate patient selection for expensive new drugs, a comprehensive examination of the financial consequences of a proposed treatment regimen is critical.
In conclusion, although the EGFR inhibitor G did not reduce the incidence of distant metastases when incorporated into our multimodality therapy for locally advanced esophageal cancer, the possible impact on survival is intriguing. Patient tolerance of a 2-year course of maintenance therapy was suboptimal. Although further investigation into the use of these agents in esophageal carcinoma is of considerable interest, identification of specific patient and molecular characteristics associated with possible drug activity is critical.
